Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Marijuana Stock Insys Therapeutics Briefly Plunged As Much As 11%

By Sean Williams – Updated May 10, 2017 at 5:02PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Mounting Subsys concerns carried over from its Q1 earnings report led to a volatile session for Insys.

What happened

Shares of Insys Therapeutics (INSY), a biopharmaceutical company that develops medicines to treat pain and other supportive-care products, tumbled by as much as 11% during Wednesdays trading session before recovering to finish lower by less than 2%. The reason for the volatile trading can probably be traced to carryover from the company's first-quarter earnings release before the opening bell on Tuesday.

So what

For the quarter, Insys wound up reporting $36 million in sales, which was down by more than 40% from the $60.4 million recorded in Q1 2016. Insys has been struggling as allegations and lawsuits surrounding Subsys, its sublingual breakthrough cancer-pain medication, have mounted. These suits suggest that the bulk of Subsys' sales were being made for off-label indications. In response, Subsys' sales have taken a big hit in recent quarters. In fact, the company took a $2.1 million charge in Q1 2017 for "excess and obsolete Subsys inventory." Comparatively, Wall Street had been looking for $37.8 million in sales.

An investor using a magnifying glass to examine a company's balance sheet.

Image source: Getty Images.

As Subsys sales have dropped, so has Insys' bottom line. The company wound up reporting a net loss of $6.5 million, or $0.09 per share, which reversed a year-ago profit of $2.3 million, or $0.03 per share. The $0.09-per-share loss was actually $0.01 better than expected.

The reason we're seeing such concern from investors is there's no clear indication when Insys' Subsys issues will be resolved. The company has already reduced its research-and-development expenses, but when Subsys' sales are tracking nearly 50% lower than they were less than two years ago, no amount of cost cuts has been able to return Insys back to profitability.

Now what

The potential saving grace and wild card for Insys is going to be Syndros, an oral dronabinol solution that was approved by the Food and Drug Administration to treat chemotherapy-induced nausea and vomiting and anorexia associated with AIDS last summer. This drug is essentially a pharmaceutical version of tetrahydrocannabinol (THC), the psychoactive component of cannabis.

A marijuana bud sitting atop a pile of cash.

Image source: Getty Images.

The hold-up for Syndros' launch had been its need for scheduling from the U.S. Drug Enforcement Agency (DEA). Earlier this year, the DEA categorized Syndros as a Schedule II product, clearing the way for a second-half-of-2017 launch. Some estimates suggest this marijuana-based drug could yield $300 million or more in peak annual sales, which would be a near-complete replacement of Subsys sales at their peak.

If Insys can stabilize Subsys' sales, put litigation surrounding Subsys in the past, and successfully launch Syndros later this year, it could become an intriguing turnaround candidate. What investors have to realize, though, is this will be a multi-year turnaround, and not something that'll happen overnight. This Fool would encourage biotech investors and those interested in marijuana stocks to add Insys Therapeutics to their watchlist. 

Sean Williams has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Insys Therapeutics Stock Quote
Insys Therapeutics
INSY

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
356%
 
S&P 500 Returns
118%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.